Development, implementation, and evaluation of a community- and hospital-based respiratory syncytial virus prophylaxis program

Advances in Neonatal Care

Volumn 5, Issue 1, 2005, Pages 39-49

  Bracht, Marianne ^a   Heffer, Michael ^a,b   O'Brien, Karel ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Antibodies monoclonal; Infant; Inpatient; Interprofessional relations; Neonatal nursing; Palivizumab; Pharmacists; Premature; Program development; Program evaluation; Program logic model; Prophylaxis; Respiratory syncytial virus

Indexed keywords

PALIVIZUMAB;

CONSENSUS; FOLLOW UP; HEALTH CARE; HEALTH CARE COST; HEALTH CARE PERSONNEL; HEALTH PROGRAM; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; NEWBORN INTENSIVE CARE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME; VIRUS INFECTION;

ANTIBIOTIC PROPHYLAXIS; DELIVERY OF HEALTH CARE; FOLLOW-UP STUDIES; HUMANS; INFANT, NEWBORN; INPATIENTS; INTENSIVE CARE UNITS, NEONATAL; LOGISTIC MODELS; PATIENT EDUCATION; PROGRAM EVALUATION; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS;

EID: 15944387768     PISSN: 15360903     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.adnc.2004.10.005     Document Type: Review

References (24)

1. C.A. Heilman National Institute of Allergy and Infectious Diseases World Health Organization Respiratory syncytial and parainfluenza viruses J Infect Dis. 161 1990 402 406
2. C.B. Hall Respiratory syncytial virus R.D. Feigin J.D. Cherry Textbook of Pediatric Infectious Diseases 1992 WB Saunders Philadelphia, Pa 1633 1656
3. The IMpact-RSV Study Group Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants Pediatrics 102 1998 531 537
4. E.L. Wang, B.J. Law, D. Stephens Pediatric Investigators Collaborative Network on Infectious Diseases in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection J Pediatr 126 1995 212 219
5. Canadian Pediatric Society Infectious Diseases and Immunization Committee Use of palivizumab in children with congenital heart disease. A joint statement with the fetus and newborn committee Paediatr Child Health 8 2003 632 633
6. N.E. MacDonald, C.B. Hal, S.C. Suffin, C. Alexson, P.J. Harris Respiratory syncytial viral infection in infants with congenital heart disease N Engl J Med. 307 1982 397 400
7. P.L. Ogra, J.P. Patel Respiratory syncytial virus infection and the immunocompromised host Pediatr Infect Dis J. 7 1988 246 249
8. T. Blydt-Hanson, K. Subbarao, P. Quennec, J. McDonald Recovery of respiratory syncytial virus from stethoscopes by conventional viral culture and polymerase chain reaction Pediatr Infect Dis J. 18 1999 164 165
9. C.B. Hall Nosocomial respiratory syncytial virus infections the "Cold War" has not ended Clin Infect Dis. 31 2000 590 596
10. B. Cohen, L. Saiman, J. Cimiotti, E. Larson Factors associated with hand hygiene practices in two neonatal intensive care units Pediatr Infect Dis J. 22 2003 494 499
11. R.A. Cox, P. Rao, C. Brandon-Cox The use of palivizumab monoclonal antibody to control an outbreak of respiratory syncytial virus infection in a special care baby unit J Hosp Infect. 48 2001 186 192
12. A.T. Heerens, D.D. Marshall, C.L. Bose Nosocomial respiratory syncytial virus a threat in the modern neonatal intensive care unit J Perinatol. 22 2002 306 307
13. C. Abadesso, H.I. Almeida, D. Virella, M.H. Carriero, M.C. Machado Use of palivizumab to control an outbreak of syncytial respiratory virus in a neonatal intensive care unit J Hosp Infect. 58 2004 38 41
14. W.P. Glezen, L.H. Taber, A.L. Frank, J.A. Kasel Risk of primary infection and reinfection with respiratory syncytial virus Am J Dis Child 140 1986 543 546
15. R.T. Stein, D. Sherrill, W.J. Morgan, C.J. Holberg, M. Halonen Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years Lancet 354 1999 541 545
16. N. Sigurs A cohort of children hospitalized with acute RSV bronchiolitis impact on later respiratory disease Paediatr Respir Rev. 3 2002 177 183
17. Canadian Pediatric Society Palivizumab and respiratory syncytial virus immune globulin intravenous for the prophylaxis of respiratory syncytial virus infection in high risk infants. A joint statement with the fetus and newborn committee Paediatr Child Health 4 1999 474 480
18. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections Pediatrics 112 2003 1442 1446
19. M. Sorrentino, T. Powers Palivizumab Outcomes Study Group Effectiveness of palivizumab evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season Pediatr Infect Dis J. 19 2000 1068 1071
20. P. Ho, K.L. Lanctot, A. Yoon, D.S.C. Lee, B.A. Paes Palivizumab prophylaxis for respiratory syncytial virus in Canada utilization and outcomes Pediatr Infect Dis. 21 2002 1 2
21. E.A. Simoes, J.R. Groothuis Respiratory syncytial virus prophylaxis--the story so far Respir Med. 96 suppl 2002 S15 S24
22. J.M. Langley, E.E. Wang, B.J. Law, D. Stephens, F.D. Boucher Economic evaluation of respiratory syncytial virus infection in Canadian children a Pediatric Investigators Collaborative Network on Infectious Diseases in Canada (PICNIC) study J Pediatr. 131 1997 113 117
23. The PREVENT Study Group Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis Pediatrics. 99 1997 93 99
24. J.J. Dwyer, S. Makin Using a program logic model that focuses on performance measurement to develop a program Can J Public Health 88 1997 421 425